Response to PD-1 inhibitor in SMARCB1‑deficient undifferentiated rectal carcinoma with low TMB, proficient MMR and BRAF V600E mutation: a case report and literature review.

Authors:
Shen W; Pan Y; Zou S.

Journal:
Diagn Pathol

Publication Year: 2024

DOI:
10.1186/s13000-023-01415-8

PMCID:
PMC10785529

PMID:
38217014

Journal Information

Full Title: Diagn Pathol

Abbreviation: Diagn Pathol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pathology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThe use of human samples was approved by the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. The data used in this research are part of standard-of-care hospital routine. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding This work was supported by National Natural Science Foundation of China (NSFC) No. 81903019 and CAMS Innovation Fund for Medical Sciences (CIFMS) No. 2021-I2M-C&TA-017."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025